RESUMEN
Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencapsulate islets from different sources that allow their survival and function without immunosuppression. Here we report successful and safe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates without any immune suppression. This strategy should lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, thereby, represents a previously unidentified approach to efficient cell replacement for a broad spectrum of endocrine disorders and other organ dysfunctions.
Asunto(s)
Diabetes Mellitus Experimental/cirugía , Diabetes Mellitus Tipo 1/cirugía , Diabetes Mellitus Tipo 1/terapia , Islotes Pancreáticos/cirugía , Animales , Femenino , Terapia de Inmunosupresión/métodos , Trasplante de Islotes Pancreáticos/métodos , Primates , Porcinos , Trasplante Heterólogo/métodosRESUMEN
Macroencapsulation devices provide the dual possibility of immunoprotecting transplanted cells while also being retrievable, the latter bearing importance for safety in future trials with stem cell-derived cells. However, macroencapsulation entails a problem with oxygen supply to the encapsulated cells. The ßAir device solves this with an incorporated refillable oxygen tank. This phase 1 study evaluated the safety and efficacy of implanting the ßAir device containing allogeneic human pancreatic islets into patients with type 1 diabetes. Four patients were transplanted with 1-2 ßAir devices, each containing 155 000-180 000 islet equivalents (ie, 1800-4600 islet equivalents per kg body weight), and monitored for 3-6 months, followed by the recovery of devices. Implantation of the ßAir device was safe and successfully prevented immunization and rejection of the transplanted tissue. However, although beta cells survived in the device, only minute levels of circulating C-peptide were observed with no impact on metabolic control. Fibrotic tissue with immune cells was formed in capsule surroundings. Recovered devices displayed a blunted glucose-stimulated insulin response, and amyloid formation in the endocrine tissue. We conclude that the ßAir device is safe and can support survival of allogeneic islets for several months, although the function of the transplanted cells was limited (Clinicaltrials.gov: NCT02064309).
Asunto(s)
Órganos Bioartificiales , Diabetes Mellitus Tipo 1/terapia , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos/citología , Páncreas Artificial , Adolescente , Glucemia/análisis , Cápsulas , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Masculino , Monitoreo Fisiológico , PronósticoRESUMEN
Current treatment options for adrenal insufficiency are limited to corticosteroid replacement therapies. However, hormone therapy does not replicate circadian rhythms and has unpleasant side effects especially due to the failure to restore normal function of the hypothalamic-pituitary-adrenal (HPA) axis. Adrenal cell transplantation and the restoration of HPA axis function would be a feasible and useful therapeutic strategy for patients with adrenal insufficiency. We created a bioartificial adrenal with 3D cell culture conditions by encapsulation of bovine adrenocortical cells (BACs) in alginate (enBACs). We found that, compared with BACs in monolayer culture, encapsulation in alginate significantly increased the life span of BACs. Encapsulation also improved significantly both the capacity of adrenal cells for stable, long-term basal hormone release as well as the response to pituitary adrenocorticotropic hormone (ACTH) and hypothalamic luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6]LHRH. The enBACs were transplanted into adrenalectomized, immunodeficient, and immunocompetent rats. Animals received enBACs intraperitoneally, under the kidney capsule (free cells or cells encapsulated in alginate slabs) or s.c. enclosed in oxygenating and immunoisolating ßAir devices. Graft function was confirmed by the presence of cortisol in the plasma of rats. Both types of grafted encapsulated cells, explanted after 21-25 d, preserved their morphology and functional response to ACTH stimulation. In conclusion, transplantation of a bioartificial adrenal with xenogeneic cells may be a treatment option for patients with adrenocortical insufficiency and other stress-related disorders. Furthermore, this model provides a microenvironment that ensures 3D cell-cell interactions as a unique tool to investigate new insights into cell biology, differentiation, tissue organization, and homeostasis.
Asunto(s)
Corteza Suprarrenal/citología , Corteza Suprarrenal/trasplante , Alginatos/farmacología , Corteza Suprarrenal/ultraestructura , Animales , Órganos Bioartificiales , Bovinos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Células Inmovilizadas/citología , Células Inmovilizadas/efectos de los fármacos , Femenino , Glucocorticoides/uso terapéutico , Ácido Glucurónico/farmacología , Ácidos Hexurónicos/farmacología , Terapia de Reemplazo de Hormonas , Ratas Desnudas , Ratas Wistar , Reproducibilidad de los Resultados , Factores de Tiempo , Tretinoina/farmacología , Pamoato de Triptorelina/farmacologíaRESUMEN
BACKGROUND: To prevent transmission of zoonotic microorganisms from pig transplants to human recipients when performing xenotransplantation using pig cells, tissues, or organs, donor pigs have to be carefully characterized. Göttingen minipigs (GöMP) are often used for various biomedical investigations and are well characterized concerning the presence of numerous bacteria, fungi, viruses, and parasites. Recently, we studied the prevalence and expression of porcine endogenous retroviruses and the prevalence of hepatitis E virus (HEV) in GöMP. Here, we studied the presence of the porcine cytomegalovirus (PCMV) and porcine lymphotropic herpesviruses (PLHV) and extended testing for hepatitis E virus (HEV). METHODS: PCR, nested PCR, real-time PCR, real-time RT-PCR, and Western blot analyses were used to estimate the prevalence of PCMV, PLHV-1, PLHV-2, PLHV-3, and HEV. RESULTS: Using different PCR methods, and different source materials, PCMV was found in 10 of 26 adult GöMP, which had been derived originally by cesarean section and kept under specified pathogen-free conditions. Only highly sensitive methods gave positive results, not methods of lower sensitivity. The virus load in all positive animals was low (<100-200 copies per mL). PLHV-1, PLHV-2, and PLHV-3 were not detected by PCR; however, an anti-PLHV immune response was found in one of 10 animals tested by Western blot analyses. HEV was detected by RT-PCR in two of nine tested animals, but no anti-HEV immune response was observed. CONCLUSION: Using highly sensitive methods, PCMV, HEV, and PLHV were found in some GöMP, suggesting that these viruses may be introduced through the placenta. The results show that highly sensitive methods are required to characterize pigs to be used for xenotransplantation to prevent virus transmission.
Asunto(s)
Citomegalovirus/fisiología , Virus de la Hepatitis E/fisiología , Herpesviridae/fisiología , Porcinos Enanos/virología , Trasplante Heterólogo , Animales , Modelos Animales de Enfermedad , Transmisión de Enfermedad Infecciosa/prevención & control , Humanos , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Porcinos , Trasplante Heterólogo/métodosRESUMEN
BACKGROUND: Xenotransplantation using pig cells, tissues or organs may be associated with the transmission of porcine zoonotic micro-organisms. Hepatitis E virus (HEV), porcine cytomegalovirus (PCMV) and porcine endogenous retroviruses (PERVs) are potentially zoonotic micro-organisms which do not show clinical symptoms in pigs and which are due to the low expression level difficult to detect. Göttingen Minipigs (GöMP) are often used for biomedical investigations and they are well characterized concerning the presence of numerous bacteria, fungi, viruses and parasites and therefore may be used for islet cell transplantation. METHODS: Islet cells derived from three GöMP were transplanted into four healthy, non-diabetic cynomolgus monkeys using a macroencapsulation device. PCR, nested PCR, real-time PCR, real-time RT-PCR and Western blot analyses were used to estimate the presence of PERV, PCMV and HEV in the donors and recipients. RESULTS: Using sensitive detection methods, no HEV was found in the donor pigs and in the pig islet cell preparations. Antibodies against PERV, PCMV and HEV were not found in all cynomolgus monkeys with exception of one monkey showing an immune response against HEV. Using real-time PCR, no PCMV and HEV were found in the sera of all monkeys. CONCLUSION: Although the donor islet cells and the recipients were negative for HEV using PCR and Western blot analysis, in one recipient, antibodies against HEV were found, indicating infection in a single case. All recipients were negative for antibodies against PERV, and all were negative for PCMV, indicating absence of infection. As HEV was not detected in the donor pig before transplantation, a more complex and regular screening of the animals using highly sensitive methods is required to avoid virus transmission.
Asunto(s)
Islotes Pancreáticos/virología , Macaca fascicularis/virología , Porcinos Enanos/virología , Trasplante Heterólogo , Animales , Virus ADN/genética , Retrovirus Endógenos , Virus de la Hepatitis E , Trasplante de Islotes Pancreáticos/métodos , Porcinos , Trasplante Heterólogo/métodosRESUMEN
Transplantation of pancreatic islets is emerging as a successful treatment for type-1 diabetes. Its current stringent restriction to patients with critical metabolic lability is justified by the long-term need for immunosuppression and a persistent shortage of donor organs. We developed an oxygenated chamber system composed of immune-isolating alginate and polymembrane covers that allows for survival and function of islets without immunosuppression. A patient with type-1 diabetes received a transplanted chamber and was followed for 10 mo. Persistent graft function in this chamber system was demonstrated, with regulated insulin secretion and preservation of islet morphology and function without any immunosuppressive therapy. This approach may allow for future widespread application of cell-based therapies.
Asunto(s)
Órganos Bioartificiales , Diabetes Mellitus Tipo 1/terapia , Cámaras de Difusión de Cultivos , Trasplante de Islotes Pancreáticos/métodos , Péptido C/metabolismo , Prueba de Tolerancia a la Glucosa , Humanos , Inmunohistoquímica , Terapia de Inmunosupresión/métodos , Trasplante de Islotes Pancreáticos/inmunología , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Islet transplantation is a feasible therapeutic alternative for metabolically labile patients with type 1 diabetes. The primary therapeutic target is stable glycemic control and prevention of complications associated with diabetes by reconstitution of endogenous insulin secretion. However, critical shortage of donor organs, gradual loss in graft function over time, and chronic need for immunosuppression limit the indication for islet transplantation to a small group of patients. Here we present a promising approach to address these limitations by utilization of a macrochamber specially engineered for islet transplantation. The s.c. implantable device allows for controlled and adequate oxygen supply and provides immunological protection of donor islets against the host immune system. The minimally invasive implantable chamber normalized blood glucose in streptozotocin-induced diabetic rodents for up to 3 mo. Sufficient graft function depended on oxygen supply. Pretreatment with the growth hormone-releasing hormone (GHRH) agonist, JI-36, significantly enhanced graft function by improving glucose tolerance and increasing ß-cell insulin reserve in rats thereby allowing for a reduction of the islet mass required for metabolic control. As a result of hypervascularization of the tissue surrounding the device, no relevant delay in insulin response to glucose changes has been observed. Consequently, this system opens up a fundamental strategy for therapy of diabetes and may provide a promising avenue for future approaches to xenotransplantation.
Asunto(s)
Hormona Liberadora de Hormona del Crecimiento/agonistas , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/fisiopatología , Oxígeno/metabolismo , Páncreas Artificial , Animales , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/fisiopatología , Diabetes Mellitus Experimental/terapia , Hormona Liberadora de Hormona del Crecimiento/metabolismo , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Trasplante de Islotes Pancreáticos , Ensayo de Materiales , Control de Calidad , RatasRESUMEN
BACKGROUND: To establish the safety of xenotransplantation when cells, tissues, or organs of pigs are used, an effective screening for potential zoonotic microorganisms has to be performed. In doing so, special attendance has to be paid to porcine endogenous retroviruses (PERVs) that are widely distributed as proviruses in the genome of pigs. PERV-A and PERV-B are present in all pigs, they infect human cells in vitro and therefore represent a direct risk. PERV-C infects only pig cells; however, recombinant PERV-A/C infecting human cells and replicating at a higher rate were found in pigs indicating an indirect risk. To prevent the transmission of PERV, it was suggested to use animals characterized by a low expression of PERV-A and PERV-B that are free of PERV-C and cannot generate recombinants. Göttingen minipigs are used for numerous biomedical investigations and they are well characterized; however, the prevalence and the expression of PERV in these animals were not yet investigated. METHODS: The presence and expression of all PERVs including a new variant (nv) of PERV-C and PERV-A/C were analyzed using PCR and real-time PCR methods. Altogether, 15 animals belonging to different families were analyzed. To make a low expression better measurable, peripheral blood mononuclear cells (PBMCs) of the animals were stimulated with phytohaemagglutinin generally increasing the expression of PERV and allowing a better classification into animals with high and low expression. As a major end point, the release of virus particles able to infect susceptible human 293 cells was investigated. RESULTS: PERV-A, PERV-B, PERV-C, and PERV-Cnv were found in the genome of all investigated Göttingen minipigs, but recombinant PERV-A/Cs were not found. When the expression of PERV was compared with that in previously analyzed pig strains, it was higher than in German landrace and some other pigs, but lower than in Yucatan miniature pigs. Virus particles able to infected human 293 cells were not detected even after mitogen treatment of the PBMCs. CONCLUSION: The Göttingen minipigs are well defined concerning their physiologic parameters, their health status, and their genetics, and therefore, they may be considered as donor animals for at least cell xenotransplantation. When the prevalence and the expression of PERVs were analyzed in these animals, it was demonstrated that although PERV-A, -B, and -C proviruses were found in all animals, their expression was low. Additional investigations are required to assess the suitability of Göttingen minipigs and other animals for xenotransplantation in terms of microbiological safety.
Asunto(s)
Retrovirus Endógenos/aislamiento & purificación , Porcinos Enanos/genética , Porcinos Enanos/virología , Trasplante Heterólogo/efectos adversos , Animales , ADN Viral/genética , ADN Viral/aislamiento & purificación , Selección de Donante , Retrovirus Endógenos/clasificación , Retrovirus Endógenos/genética , Femenino , Células HEK293 , Humanos , Masculino , Seguridad , Especificidad de la Especie , Porcinos , Donantes de Tejidos , Zoonosis/prevención & control , Zoonosis/transmisión , Zoonosis/virologíaRESUMEN
Transplantation of encapsulated islets can cure diabetes without immunosuppression, but oxygen supply limitations can cause failure. We investigated a retrievable macroencapsulation device wherein islets are encapsulated in a planar alginate slab and supplied with exogenous oxygen from a replenishable gas chamber. Translation to clinically-useful devices entails reduction of device size by increasing islet surface density, which requires increased gas chamber pO2. Here we show that islet surface density can be substantially increased safely by increasing gas chamber pO2 to a supraphysiological level that maintains all islets viable and functional. These levels were determined from measurements of pO2 profiles in islet-alginate slabs. Encapsulated islets implanted with surface density as high as 4,800 islet equivalents/cm3 in diabetic rats maintained normoglycemia for more than 7 months and provided near-normal intravenous glucose tolerance tests. Nearly 90% of the original viable tissue was recovered after device explantation. Damaged islets failed after progressively shorter times. The required values of gas chamber pO2 were predictable from a mathematical model of oxygen consumption and diffusion in the device. These results demonstrate feasibility of developing retrievable macroencapsulated devices small enough for clinical use and provide a firm basis for design of devices for testing in large animals and humans.
Asunto(s)
Supervivencia Celular/fisiología , Trasplante de Islotes Pancreáticos/fisiología , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/fisiología , Oxígeno/metabolismo , Alginatos/metabolismo , Animales , Glucemia/metabolismo , Glucemia/fisiología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/fisiopatología , Prueba de Tolerancia a la Glucosa/métodos , Supervivencia de Injerto/fisiología , Terapia de Inmunosupresión/métodos , Masculino , Consumo de Oxígeno/fisiología , Ratas , Ratas Endogámicas LewRESUMEN
At present, proven clinical treatments but no cures are available for diabetes, a global epidemic with a huge economic burden. Transplantation of islets of Langerhans by their infusion into vascularized organs is an experimental clinical protocol, the first approach to attain cure. However, it is associated with lifelong use of immunosuppressants. To overcome the need for immunosuppression, islets are encapsulated and separated from the host immune system by a permselective membrane. The lead material for this application is alginate which was tested in many animal models and a few clinical trials. This review discusses all aspects related to the function of transplanted encapsulated islets such as the basic requirements from a permselective membrane (e.g., allowable hydrodynamic radii, implications of the thickness of the membrane and relative electrical charge). Another aspect involves adequate oxygen supply, which is essential for survival/performance of transplanted islets, especially when using large retrievable macro-capsules implanted in poorly oxygenated sites like the subcutis. Notably, islets can survive under low oxygen tension and are physiologically active at > 40 Torr. Surprisingly, when densely crowded, islets are fully functional under hyperoxic pressure of up to 500 Torr (> 300% of atmospheric oxygen tension). The review also addresses an additional category of requirements for optimal performance of transplanted islets, named auxiliary technologies. These include control of inflammation, apoptosis, angiogenesis, and the intra-capsular environment. The review highlights that curing diabetes with a functional bio-artificial pancreas requires optimizing all of these aspects, and that significant advances have already been made in many of them.
RESUMEN
Islet transplantation effectively treats diabetes but relies on immune suppression and is practically limited by the number of cadaveric islets available. An alternative cellular source is insulin-producing cells derived from pluripotent cell sources. Three animal cohorts were used in the current study to evaluate whether an oxygen-providing macro-encapsulation device, 'ßAIR', could function in conjunction with human embryonic stem cells (hESCs) and their derivatives. The first cohort received macro-encapsulated undifferentiated hESCs, a second cohort received hESCs differentiated to a pancreatic progenitor state with limited endocrine differentiation. A reference cohort received human islets. Macro-encapsulation devices were implanted subcutaneously and monitored for up to 4 months. Undifferentiated pluripotent stem cells did not form teratoma but underwent cell death following implantation. Human C-peptide (hC- peptide) was detectable in host serum one week after implantation for both other cohorts. hC-peptide levels decreasing over time but remained detectable up to the end of the study. Key factors associated with mature endocrine cells were observed in grafts recovered from cohorts containing islets and hESC-derivatives including C-peptide, insulin, glucagon and urocortin 3. We conclude that the 'ßAIR' macroencapsulation device is compatible with both human islets and pluripotent derivatives, but has a limited capability of sustaining undifferentiated pluripotent cells.
RESUMEN
Xenotransplantation has been proposed as a solution to the shortage of suitable human donors. Pigs are currently favoured as donor animals for xenotransplantation of cells, including islet cells, or organs. To reduce the xenotransplantation-associated risk of infection of the recipient the pig donor should be carefully characterised. Göttingen minipigs from Ellegaard are often used for biomedical research and are regularly tested by their vendor for the presence of numerous bacteria, fungi, viruses and parasites. However, screening for some pathogens transmittable to humans had not been performed.The presence of microorganisms was examined in Göttingen Minipigs by PCR methods. Since zoonotic transmission of porcine hepatitis E virus HEV to humans has been demonstrated, extended search for HEV was considered as a priority. RNA from sera, islet and other cells from 40 minipigs were examined for HEV using different real-time reverse transcription (RT)-PCRs, among them two newly established. In addition, sera were examined by Western blot analysis using two recombinant capsid proteins of HEV as antigens. HEV RNA was not detected in pigs older than one year including gilts, but it was detected in the sera of three of ten animals younger than 1 year. Furthermore, HEV was also detected in the sera of three sows six days after delivery and their offspring, indicating vertical transmission of the virus. PCR amplicons were cloned, sequenced and the viruses were found to belong to the HEV genotype (gt) 3/4. Anti-HEV immunoglobulins G were detected in one sow and maternal antibodies in her six day old piglet. Since Göttingen minipigs were negative for many xenotransplantation-relevant microorganisms, they can now be classified as safe. HEV may be eliminated from the Ellegaard herd by selection of negative animals and/or by treatment of the animals.
Asunto(s)
Virus de la Hepatitis E/aislamiento & purificación , Hepatitis E/microbiología , Porcinos Enanos/microbiología , Trasplante Heterólogo/efectos adversos , Animales , Genotipo , Anticuerpos Antihepatitis/sangre , Hepatitis E/transmisión , Virus de la Hepatitis E/patogenicidad , Humanos , ARN Viral/sangre , Porcinos , Enfermedades de los Porcinos/virología , Porcinos Enanos/inmunologíaRESUMEN
The current epidemic of diabetes with its overwhelming burden on our healthcare system requires better therapeutic strategies. Here we present a promising novel approach for a curative strategy that may be accessible for all insulin-dependent diabetes patients. We designed a subcutaneous implantable bioartificial pancreas (BAP)-the "ß-Air"-that is able to overcome critical challenges in current clinical islet transplantation protocols: adequate oxygen supply to the graft and protection of donor islets against the host immune system. The system consists of islets of Langerhans immobilized in an alginate hydrogel, a gas chamber, a gas permeable membrane, an external membrane, and a mechanical support. The minimally invasive implantable device, refueled with oxygen via subdermally implanted access ports, completely normalized diabetic indicators of glycemic control (blood glucose intravenous glucose tolerance test and HbA1c) in streptozotocin-induced diabetic rats for periods up to 6 months. The functionality of the device was dependent on oxygen supply to the device as the grafts failed when oxygen supply was ceased. In addition, we showed that the device is immuno-protective as it allowed for survival of not only isografts but also of allografts. Histological examination of the explanted devices demonstrated morphologically and functionally intact islets; the surrounding tissue was without signs of inflammation and showed visual evidence of vasculature at the site of implantation. Further increase in islets loading density will justify the translation of the system to clinical trials, opening up the potential for a novel approach in diabetes therapy.
Asunto(s)
Islotes Pancreáticos/efectos de los fármacos , Oxígeno/farmacología , Páncreas Artificial , Supervivencia Tisular/efectos de los fármacos , Aloinjertos/efectos de los fármacos , Animales , Glucemia/metabolismo , Fibrosis/patología , Prueba de Tolerancia a la Glucosa , Hemoglobina Glucada/metabolismo , Implantes Experimentales , Insulina/metabolismo , Masculino , Ensayo de Materiales , Implantación de Prótesis , Ratas , Ratas Endogámicas Lew , Ratas Sprague-Dawley , Tejido Subcutáneo/efectos de los fármacos , Trasplante HomólogoRESUMEN
Developing a device that protects xenogeneic islets to allow treatment and potentially cure of diabetes in large mammals has been a major challenge in the past decade. Using xenogeneic islets for transplantation is required in light of donor shortage and the large number of diabetic patients that qualify for islet transplantation. Until now, however, host immunoreactivity against the xenogeneic graft has been a major drawback for the use of porcine islets. Our study demonstrates the applicability of a novel immunoprotective membrane that allows successful xenotransplantation of rat islets in diabetic minipigs without immunosuppressive therapy. Rat pancreatic islets were encapsulated in highly purified alginate and integrated into a plastic macrochamber covered by a poly-membrane for subcutaneous transplantation. Diabetic Sinclair pigs were transplanted and followed for up to 90 days. We demonstrated a persistent graft function and restoration of normoglycemia without the need for immunosuppressive therapy. This concept could potentially offer an attractive strategy for a more widespread islet replacement therapy that would restore endogenous insulin secretion in diabetic patients without the need for immunosuppressive drugs and may even open up an avenue for safe utilization of xenogeneic islet donors.